Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD).
In recent years, research has focused on the pre-dementia stages of cognitive impairment in …

Background Common genetic variance in apolipoprotein E (APOE), β‐glucocerebrosidase
(GBA), microtubule‐associated protein tau (MAPT), and α‐synuclein (SNCA) has been …

Mild cognitive impairment (PD-MCI) and dementia (PDD) are among the most frequent non-
motor symptoms in Parkinson's disease (PD). PD-MCI is six times more likely than age …

Neuropsychological (mostly posterior-cortical) deficits, quantitative magnetic resonance
imaging (MRI) atrophy patterns, and low cerebrospinal fluid (CSF) levels of amyloid-β have …

Objective To assess regions and patterns of brain atrophy in patients with Parkinson disease
(PD) with normal cognition (PD-NC), mild cognitive impairment (PD-MCI), and dementia …

Dementia in Parkinson's disease affects 50% of patients within 10 years of diagnosis but
there is wide variation in severity and timing. Thus, robust neuroimaging prediction of …

Importance Cognitive impairment is a common and disabling problem in Parkinson disease
(PD) that is not well understood and is difficult to treat. Identification of genetic variants that …

Introduction Cognitive impairment is a debilitating manifestation in Parkinson's disease (PD).
We sought to investigate predictors of PD-CI (PD with cognitive impairment). Methods We …

Objective: Cognitive decline associated with Parkinson disease (PD) is common and highly
disabling. Biomarkers that help identify patients at risk for cognitive decline would be useful …

Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …